Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,199,245
  • Shares Outstanding, K 37,961
  • Annual Sales, $ 64,730 K
  • Annual Income, $ -78,820 K
  • 60-Month Beta 2.58
  • Price/Sales 64.93
  • Price/Cash Flow N/A
  • Price/Book 8.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.17
  • Number of Estimates 7
  • High Estimate -0.70
  • Low Estimate -1.58
  • Prior Year -1.25
  • Growth Rate Est. (year over year) +6.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
109.86 +0.69%
on 04/18/19
114.11 -3.06%
on 04/02/19
-3.34 (-2.93%)
since 03/18/19
3-Month
40.64 +172.19%
on 01/29/19
114.20 -3.13%
on 03/12/19
+65.54 (+145.39%)
since 01/18/19
52-Week
34.53 +220.36%
on 12/26/18
114.20 -3.13%
on 03/12/19
+29.17 (+35.81%)
since 04/18/18

Most Recent Stories

More News
Spark Therapeutics Announces Sponsorship of Believe Limited's First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation's Bleeding Disorders Conference

Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it will serve as the inaugural...

ONCE : 110.62 (-0.08%)
Spark Therapeutics (ONCE) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spark Therapeutics, Inc. Concerning Its Proposed Merger With Roche Holdings, Inc. - ONCE

Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spark Therapeutics, Inc. ("Spark" or the "Company") (NASDAQ: ONCE) in connection...

ONCE : 110.62 (-0.08%)
Ophthotech Gets Rights to Gene Therapy for BEST Disease

Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

ONCE : 110.62 (-0.08%)
OPHT : 1.39 (-0.71%)
NVS : 76.41 (-1.15%)
RHHBY : 32.6900 (-0.09%)
Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

BBP : 41.17 (-0.32%)
SBIO : 33.66 (+0.18%)
ARKG : 32.12 (+0.44%)
ONCE : 110.62 (-0.08%)
ILMN : 319.03 (+0.11%)
JNJ : 137.52 (-0.72%)
LLY : 115.20 (-1.12%)
NVS : 76.41 (-1.15%)
RHHBY : 32.6900 (-0.09%)
PFE : 39.38 (-1.25%)
XBI : 84.63 (-0.24%)
BTEC : 32.08 (-0.56%)
Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

BBP : 41.17 (-0.32%)
SBIO : 33.66 (+0.18%)
ARKG : 32.12 (+0.44%)
ONCE : 110.62 (-0.08%)
ILMN : 319.03 (+0.11%)
JNJ : 137.52 (-0.72%)
LLY : 115.20 (-1.12%)
NVS : 76.41 (-1.15%)
RHHBY : 32.6900 (-0.09%)
PFE : 39.38 (-1.25%)
XBI : 84.63 (-0.24%)
BTEC : 32.08 (-0.56%)
Recent Analysis Shows A. O. Smith, Plains Group Holdings, The Hackett Group, Ryder System, MUELLER WATER PRODUCTS, and Spark Therapeutics Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of A. O. Smith Corporation...

R : 65.57 (+0.02%)
ONCE : 110.62 (-0.08%)
AOS : 56.49 (+0.88%)
HCKT : 15.29 (+0.13%)
MWA : 10.99 (-0.27%)
PAGP : 24.15 (-1.11%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
SRPT : 116.64 (-1.76%)
OPHT : 1.39 (-0.71%)
NITE : 25.51 (+0.04%)
RGNX : 54.65 (-0.13%)
BOLD : 38.90 (+0.96%)
Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

CELG : 93.76 (-0.57%)
VHT : 161.47 (+0.20%)
XLV : 85.92 (+0.16%)
ONCE : 110.62 (-0.08%)
NITE : 25.51 (+0.04%)
BBH : 120.20 (-0.74%)
BMY : 45.52 (-0.61%)
BTEC : 32.08 (-0.56%)
LLY : 115.20 (-1.12%)
FBT : 136.53 (-0.72%)
IYH : 181.00 (+0.17%)
GSK : 39.85 (-0.33%)
XBI : 84.63 (-0.24%)
Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

CELG : 93.76 (-0.57%)
VHT : 161.47 (+0.20%)
XLV : 85.92 (+0.16%)
ONCE : 110.62 (-0.08%)
NITE : 25.51 (+0.04%)
BBH : 120.20 (-0.74%)
BMY : 45.52 (-0.61%)
BTEC : 32.08 (-0.56%)
LLY : 115.20 (-1.12%)
FBT : 136.53 (-0.72%)
IYH : 181.00 (+0.17%)
GSK : 39.85 (-0.33%)
XBI : 84.63 (-0.24%)
Rigrodsky & Long, P.A. Files Class Action Suit Against Spark Therapeutics, Inc.

Rigrodsky & Long, P.A.:

ONCE : 110.62 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ONCE with:

Business Summary

Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in...

See More

Key Turning Points

2nd Resistance Point 111.57
1st Resistance Point 111.09
Last Price 110.62
1st Support Level 110.00
2nd Support Level 109.39

See More

52-Week High 114.20
Last Price 110.62
Fibonacci 61.8% 83.77
Fibonacci 50% 74.36
Fibonacci 38.2% 64.96
52-Week Low 34.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar